4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000043
Director sold 105,000 shares at an average $58.97 ($6,191,366)
- Director acquired 62,260 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Dambkowski Carl · Director
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-05-21 | Exercise or conversion : show line 1 in the form 10b5-1 | +38,689 | $6.84 | $264,633 | 155,172 | D |
| 2026-05-21 | Exercise or conversion : show line 2 in the form 10b5-1 | +11,904 | $7.80 | $92,851 | 167,076 | D |
| 2026-05-21 | Exercise or conversion : show line 3 in the form 10b5-1 | +11,667 | $11.77 | $137,321 | 178,743 | D |
| 2026-05-21 | Sale : show line 4 in the form 10b5-1 | −38,318 | $58.43 | $2,238,794 | 140,425 | D |
| 2026-05-21 | Sale : show line 5 in the form 10b5-1 | −53,447 | $59.10 | $3,158,910 | 86,978 | D |
| 2026-05-21 | Sale : show line 6 in the form 10b5-1 | −13,235 | $59.97 | $793,662 | 73,743 | D |
| Open-market sales · 105,000 sh · avg $58.97 · $6,191,366 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-05-21 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (right to buy) | −38,689 | 32,737 | D |
| 2026-05-21 | Exercise or conversion : show line 8 in the form 10b5-1 Warrant (right to buy) | −11,904 | 10,952 | D |
| 2026-05-21 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (right to buy) | −11,667 | 5,833 | D |
Loading xslF345X06/form4.xml…